| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENPP1 |
| Uniprot No | P22413 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 98-925aa |
| 氨基酸序列 | ASKPSCAKEV KSCKGRCFER TFGNCRCDAA CVELGNCCLD YQETCIEPEH IWTCNKFRCG EKRLTRSLCA CSDDCKDKGD CCINYSSVCQ GEKSWVEEPC ESINEPQCPA GFETPPTLLF SLDGFRAEYL HTWGGLLPVI SKLKKCGTYT KNMRPVYPTK TFPNHYSIVT GLYPESHGII DNKMYDPKMN ASFSLKSKEK FNPEWYKGEP IWVTAKYQGL KSGTFFWPGS DVEINGIFPD IYKMYNGSVP FEERILAVLQ WLQLPKDERP HFYTLYLEEP DSSGHSYGPV SSEVIKALQR VDGMVGMLMD GLKELNLHRC LNLILISDHG MEQGSCKKYI YLNKYLGDVK NIKVIYGPAA RLRPSDVPDK YYSFNYEGIA RNLSCREPNQ HFKPYLKHFL PKRLHFAKSD RIEPLTFYLD PQWQLALNPS ERKYCGSGFH GSDNVFSNMQ ALFVGYGPGF KHGIEADTFE NIEVYNLMCD LLNLTPAPNN GTHGSLNHLL KNPVYTPKHP KEVHPLVQCP FTRNPRDNLG CSCNPSILPI EDFQTQFNLT VAEEKIIKHE TLPYGRPRVL QKENTICLLS QHQFMSGYSQ DILMPLWTSY TVDRNDSFST EDFSNCLYQD FRIPLSPVHK CSFYKNNTKV SYGFLSPPQL NKNSSGIYSE ALLTTNIVPM YQSFQVIWRY FHDTLLRKYA EERNGVNVVS GPVFDFDYDG RCDSLENLRQ KRRVIRNQEI LIPTHFFIVL TSCKDTSQTP LHCENLDTLA FILPHRTDNS ESCVHGKHDS SWVEELLMLH RARITDVEHI TGLSFYQQRK EPVSDILKLK THLPTFSQED GPKLHHHHHH |
| 预测分子量 | 97 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ENPP1重组蛋白的代表性文献示例(内容基于公开研究概括，非真实文献)：
---
1. **文献名称**：*Recombinant ENPP1 prevents vascular calcification in a murine model of pseudoxanthoma elasticum*
**作者**：Smith A, et al.
**摘要**：研究利用重组ENPP1蛋白治疗ENPP1缺失小鼠模型，发现其通过增加细胞外焦磷酸盐水平，显著抑制血管和软组织钙化，为遗传性钙化疾病提供了潜在疗法。
2. **文献名称**：*Structural and functional characterization of human ENPP1 extracellular domain expressed in HEK293 cells*
**作者**：Chen L, et al.
**摘要**：报道了在HEK293细胞中高效表达人源ENPP1胞外结构域重组蛋白的方法，并通过晶体结构解析和酶活实验，揭示了其底物结合位点及催化机制。
3. **文献名称**：*ENPP1-Fc fusion protein enhances antitumor immunity by modulating extracellular ATP levels*
**作者**：Wang Y, et al.
**摘要**：开发了ENPP1-Fc重组融合蛋白，证明其通过水解肿瘤微环境中的ATP，抑制腺苷介导的免疫抑制，增强PD-1抗体在黑色素瘤模型中的疗效。
---
**注**：以上为模拟文献，实际引用需通过PubMed/Google Scholar检索关键词“ENPP1 recombinant protein”或联系具体研究方向(如代谢疾病、癌症免疫治疗)获取真实文献。
ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) is a type II transmembrane glycoprotein that hydrolyzes extracellular nucleotides such as ATP, GTP, and cyclic nucleotides, generating pyrophosphate (PPi) and monophosphate products. It plays critical roles in regulating physiological processes, including bone mineralization, vascular calcification, and purinergic signaling. Structurally, ENPP1 consists of a short N-terminal cytoplasmic domain, a transmembrane helix, and a large extracellular enzymatic domain with two somatomedin-B-like domains and a catalytic phosphodiesterase domain. Dysregulation of ENPP1 is linked to human diseases such as generalized arterial calcification of infancy (GACI), autosomal recessive hypophosphatemic rickets, and certain cancers.
Recombinant ENPP1 protein is produced using expression systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications and enzymatic activity. Its production enables functional studies, including substrate specificity analysis, inhibitor screening, and structural characterization. Recent research highlights ENPP1's role in the tumor microenvironment, where it hydrolyzes immunostimulatory cyclic GMP-AMP (cGAMP), suppressing the STING pathway and dampening antitumor immunity. This has spurred interest in developing ENPP1 inhibitors as cancer immunotherapeutics.
Purified recombinant ENPP1 is also used in diagnostic assays and to study molecular mechanisms of calcification disorders. Its therapeutic potential extends to treating metabolic diseases, as ENPP1 variants influence insulin resistance. By providing a controlled source of enzymatically active protein, recombinant ENPP1 facilitates both basic research and drug discovery, bridging insights from molecular biology to clinical applications.
×
